The removal of the enzyme Dnmt1 during oligodendrocyte progenitor cell (OPC) differentiation in the central nervous system resulted in inefficient myelin formation and neurological deterioration, including loss of control of bodily movements, in mice, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published today in the medical journal Cell Reports. The results could lead to a new understanding of multiple sclerosis and other myelin disorders in humans.
Oligodendrocytes (OLs) are cells with the ability to form a specialized membrane that is called "myelin." Myelin is the insulating sheathing around the axons of nerve cells, which provides energetic support and allows for faster electrical impulse conduction. OLs are derived from progenitors called OPCs, which are stem-like cells with the ability to divide and generate OLs through a complex process of gene regulation.
This study shows that the development of OPCs into myelin-forming cells requires DNA methylation, which is a process consisting of the addition of chemical groups to the DNA carried out by enzymes called methyl transferases (DNMTs). When these groups are added, genes cannot be expressed and therefore are "silenced." The authors identify the many genes needed to be "silenced" in OPCs in order to allow for proper formation of myelin during development.
Researchers showed that the removal of Dnmt1 in oligodendrocyte lineage not only limited cell growth, but also led to cellular stress as well as severe and clinically symptomatic hypomelination – a reduced amount of myelin in nervous tissue. The mice experienced significant neurological symptoms, such as tremors and a loss of control of body movement, and eventually death.
"Our group has previously observed altered DNA methylation in the brain of patients with multiple sclerosis, the most devastating adult demyelinating disorder, but its role in myelin formation and the identity of the genes silenced by DNMT's in OPCs were not known," says lead investigator Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomics, and Neurology, and Chief of the Center of Excellence for Myelin Repair at the Friedman Brain Institute at the Icahn School of Medicine. "A better understanding of why DNA methylation is important for myelin formation and what genes need to be shut off during the formation of OLs from OPCs has important implications not only for development, but also for myelin repair."
The research could lead to the development of treatment for disorders where the myelin sheath is damaged and could also help in understanding how OPCs transform into brain cancer cells.
Further study is needed to understand the causes underlying aberrant DNA methylation in the brains of multiple sclerosis patients and in preclinical models. Translational applications will include the identification of factors that could bypass impaired DNA methylation.
University of Cambridge, Universit?t Erlangen-Nürnberg, Oregon Health and Science University, Sorbonne Université, University of California Los Angeles and Virginia Commonwealth University contributed to this research.
The National Institutes of Health (Award# R37NS042925) and the UK Multiple Sclerosis Society provided funding. This research does not represent the official views of the NIH.
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services–from community-based facilities to tertiary and quaternary care.
The System includes approximately 6,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is ranked as one of the nation's top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2014-2015 "Best Hospitals" issue of U.S. News & World Report. Mount Sinai's Kravis Children's Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology, while Mount Sinai Beth Israel is ranked regionally.
For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.